๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Xiangya Hospital of Central South University49 Eli Lilly and Company36 Second Xiangya Hospital of Central South University36 Hunan Province Tumor Hospital32
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Changsha

1154 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study
NCT07652489Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Eye & ENT Hospital of Fudan University
Observational
70
Harbin, Changsha, Shenyang, Shanghai, Xiโ€™an, Wenzhou
2026-06-01
Not yet open
Effects of a Acceptance and Commitment Therapy-Based Psychosocial Intervention on Mental Health of Women With Perinatal Loss: A Pilot Randomised Controlled Trial
NCT07538011ACT, Perinatal Loss, Mental Health
Second Xiangya Hospital of Central South University
Not applicable
88
Changsha
2026-06-01
Not yet open
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers
NCT07618156Healthy Volunteers (HV)
Jiangxi Kvvit Pharmaceutical Co., Ltd.
Phase 1
83
Changsha
2026-06
Not yet open
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
NCT07622342Generalized Myasthenia Gravis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
60
Changsha, Shanghai
2026-06
Not yet open
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204Recurrent/Metastatic Head and Neck Cancer
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
128
Beijing, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Taiyuan, Chengdu
2026-06
Not yet open
Effect of Biologic vs Synthetic Mesh on Chronic Pain After Laparoscopic Repair of Contralateral Asymptomatic Hernia in Patients With Unilateral Symptomatic Inguinal Hernia
NCT07649434Hernia Inguinal, Biologic Mesh
Xiangya Hospital of Central South University
Not applicable
90
Changsha
2026-06
Not yet open
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
NCT07627464Renal Cell Carcinoma (RCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
144
Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao
2026-05-31
Not yet open
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
NCT07582822Advanced Solid Tumor
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Not yet open
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
NCT07414290Parkinson Disease (PD)
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1/2
17
Changsha
2026-05-25
Recruiting
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
NCT07591298Diagnosed With HoFH
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 2
18
Changsha
2026-05-24
Recruiting
Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain
NCT07491146Pain After Abdominal Surgery
Yingyong Zhou,MD,PhD
Phase 2
200
Changsha, Chengdu
2026-05-23
Recruiting
A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery
NCT07533786Pain After Surgery
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
200
Changsha, Chengdu
2026-05-22
Recruiting
Study on iTBS Regulating the Reward Circuit Function to Improve Anhedonia in Depression
NCT07813169Major Depression, Anhedonia, Melancholic Depression, Theta Burst Stimulation
Guo Wenbin
Not applicable
60
Changsha
2026-05-19
Recruiting
Adaptive DBS for PD
NCT07635823Parkinson Disease(PD)
Beijing Pins Medical Co., Ltd
Not applicable
60
Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu
2026-05-16
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Not yet open
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC
NCT07643350NSCLC
The Third Xiangya Hospital of Central South University
Phase 2
152
Changsha
2026-05-15
Not yet open
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients
NCT07460336Latent Autoimmune Diabetes in Adults (LADA)
Second Xiangya Hospital of Central South University
Not applicable
84
Changsha
2026-05-15
Active, closed
A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.
NCT07565597Healthy
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
64
Changsha
2026-05-12
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
NCT07529626Pancreatic Tumor, Benign, Pancreatic Cancer, Adult, Pancreatic Cancer Resectable
Shanghai Zhongshan Hospital
Observational
320
Changsha, Shanghai, Xiโ€™an
2026-05-11
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals
Phase 3
5,700
Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing
2026-05-11
Recruiting
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
NCT07608003Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse Midline, H3K27M-mutant
Xiangya Hospital of Central South University
Observational
500
Changsha
2026-05-10
Not yet open
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
NCT06706219Non Small Cell Lung Cancer (Stage III)
Hunan Province Tumor Hospital
Phase 2
50
Changsha
2026-05-10
Recruiting
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery
NCT07699601Postoperative Pain
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2/3
330
Changsha
2026-05-09
Recruiting
Dymista in Chinese Adolescents
NCT07597473Allergic Rhinitis Due to Allergens
Viatris Inc.
Phase 4
100
Beijing, Changsha, Chengdu, Dalian, Hangzhou, Nanchang, Shanghai, Taiyuan
2026-05-08
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
By invitation
Precision Antithrombotic Therapy
NCT07654634Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
The Third Xiangya Hospital of Central South University
Observational
5,000
Changsha
2026-05-01
Not yet open
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2026-05-01
Not yet open
Prospective International Multi-center Clinical Trial of PGT-A Upgrade
NCT07533630Infertility Assisted Reproductive Technology
Reproductive & Genetic Hospital of CITIC-Xiangya
Observational
1,700
Changsha, Nanjing, Kunming
2026-05
Not yet open
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
NCT07557927Discoid Lupus Erythematosus
Kunming Pharmaceuticals, Inc.
Phase 2
100
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou
2026-04-30
Recruiting
A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT07338487Locally Advanced Cervical Cancer, Cachexia
Second Xiangya Hospital of Central South University
Phase 1
88
Changsha
2026-04-30
Not yet open
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
NCT07537881Solid Tumors
RemeGen Co., Ltd.
Phase 1/2
326
Changsha
2026-04-30
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161Alzheimer Disease
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
NCT07474727Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2
180
Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang
2026-04-29
Recruiting
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
NCT07520162Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Foshan
2026-04-24
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Changsha, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan
2026-04-22
Active, closed
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations
NCT07338942ATTR-CM
AstraZeneca
Not applicable
4,000
Beijing, Changlexi, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangdong Province
2026-04-21
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Not yet open
Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes
NCT07558525Prediabetes
Second Xiangya Hospital of Central South University
Not applicable
472
Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi
2026-04-18
Recruiting
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
NCT07235319Nasopharangeal Cancer, Distant Metastasis
Sun Yat-sen University
Phase 3
260
Guangzhou, Changsha, Fuzhou, Hangzhou, Nanning
2026-04-16
Recruiting
DAREON ยฎ -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
Phase โ…ข Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Recruiting
A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection
NCT07489482Diabetes Mellitus
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
60
Changsha
2026-04-02
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177Alveolar Soft Part Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.
NCT07519109Postoperative Pain
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1
60
Changsha
2026-03-30
Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
NCT07383909Aortic Dissection Type A
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
Novartis Pharmaceuticals
Phase 3
770
Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou
2026-03-24
Not yet open
Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites
NCT07475715Allergic Rhinitis Due to Dust Mite
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT07293260Cardiovascular Disease
Amgen
Phase 3
406
Beijing, Zhengzhou, Changsha, Nanjing, Yinchuan, Xi'an, Jinan
2026-03-23
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Recruiting
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
NCT07446738Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Observational
200
Changchun, Changsha, Chengdu, Guangzhou, Haikou, Kunming, Nanchang, Nanjing
2026-03-19
Recruiting
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
NCT07412691Skin Diseases
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
MK-3475AยฑCalderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT07431827Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase 2
90
Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou
2026-03-18
Recruiting
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
NCT07498478Breast Cancer
TransThera Sciences (Nanjing), Inc.
Phase 2
94
Guangzhou, Wuhan, Changsha, Nanjing, Jinan, Linyi, Hangzhou, Beijing
2026-03-17
Recruiting
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT07402239Heart Failure
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Recruiting
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
NCT07402512Respiratory Syncytial Virus Infection
Simcere Pharmaceutical Co., Ltd
Phase 3
498
Xiamen, Changsha, Chengdu, Hangzhou
2026-03-11
Recruiting
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
NCT06951646Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Recruiting
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
NCT07404202Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
AstraZeneca
Observational
2,100
Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai
2026-03-06
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua
2026-03-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Recruiting
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
NCT07396584Solid Tumors, Adult
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
NCT07436949Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Bambusa Therapeutics
Phase 1/2
64
Beijing, Guangzhou, Changsha, Nanjing, Jinan, Qingdao, Yantai, Zibo
2026-03-02
Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers
NCT07474545Healthy Volunteers
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
76
Changsha
2026-03-02
Recruiting
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
NCT07396480Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
First Affiliated Hospital of Zhejiang University
Phase 3
186
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou
2026-03-01
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
NCT07375524Primary Sjรถgren Syndrome
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou
2026-03-01
Recruiting
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol๏ผˆLDL-C๏ผ‰
NCT07368608Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
BeBetter Med Inc
Phase 1/2
340
Changsha
2026-03-01
Recruiting
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
NCT07441174Solid Tumor Cancer, PDAC
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Recruiting
Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery
NCT07412223Pain, Postoperative, Postoperative Ileus
Xiangya Hospital of Central South University
Phase 4
152
Guangzhou, Changsha
2026-02-24
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou, Jining
2026-02-09
Recruiting
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07276958Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Eli Lilly and Company
Phase 1
68
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
2026-02-04
Recruiting
Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke
NCT07369999Mild Disabling Acute Ischemic Stroke
Xiangya Hospital of Central South University
Phase 3
1,062
Changsha, Changโ€™an, Cili, Guankou, Huayuan, Lanshan, Leiyang, Pingjiang
2026-02-01
Not yet open
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE๏ผ‰
NCT07274137Overweight or Obesity
MindRank AI Ltd
Phase 3
738
Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei
2026-02
Recruiting
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07331272Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642Severe Asthma
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525Oral Tongue Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562Small for Gestational Age
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Not yet open
Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia
NCT07321535Sarcopenia
Wangjing Hospital, China Academy of Chinese Medical Sciences
Not applicable
106
Beijing, Changsha, Tianjin
2026-01-15
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
By invitation
AI-based Prediction of Prostate Cancer Metastasis Using Biopsy Pathology
NCT07660276Prostate Cancer Metastatic
Xiangya Hospital of Central South University
Observational
3,000
Changsha
2026-01-08
Recruiting
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
NCT07441993Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Recruiting
Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI
NCT07755670Hidradenitis Suppurativa (HS)
Second Xiangya Hospital of Central South University
Observational
80
Changsha
2026-01-03
Rows per page Showing 101–200 of 1154
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/changsha?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,154 of those studies with a site in Changsha.

How many clinical trials are recruiting in Changsha?

670 of the 1,154 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 112 have not yet opened recruitment, 352 are active but closed to new participants, and 20 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.